Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Reindl-Schwaighofer RCTJanssen AD26 vaccine (JNJ-78436735)Comirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
100/101 inconclusive
    MixNMatch Study
     
    NCT04889209
    OBSJanssen AD26 vaccine (JNJ-78436735)mRNA vaccineCOVID-19 prophylaxis (excluding children)NA
    -/- inconclusive
      Botton (EPI-PHARE) OBSJanssen AD26 vaccine (JNJ-78436735)Comirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
      -/- safety concern
      • statistically significant 5.7-fold increase in hospitalization

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).